Literature DB >> 22990266

FDA approval of obesity drugs: a difference in risk-benefit perceptions.

Elaine H Morrato1, David B Allison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22990266      PMCID： PMC3849814          DOI： 10.1001/jama.2012.10007

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

2.  FDA approves Belviq to treat some overweight or obese adults.

Authors: 
Journal:  Home Healthc Nurse       Date:  2012-09

3.  Perception of risk.

Authors:  P Slovic
Journal:  Science       Date:  1987-04-17       Impact factor: 47.728

4.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321
  4 in total
  5 in total

1.  The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Authors:  Anita Chawla; Ginger Carls; Edmund Deng; Edward Tuttle
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

2.  Anti-Obesity Agents and the US Food and Drug Administration.

Authors:  Martin F Casey; Jeffrey I Mechanick
Journal:  Curr Obes Rep       Date:  2014-09

3.  GUCY2C: at the intersection of obesity and cancer.

Authors:  Gilbert W Kim; Jieru E Lin; Scott A Waldman
Journal:  Trends Endocrinol Metab       Date:  2013-01-29       Impact factor: 12.015

4.  Successful Medical Weight Loss in a Community Setting.

Authors:  Douglas Carney; Stephen Schultz; Jeong Lim; William Walters
Journal:  J Obes Weight Loss Ther       Date:  2015-02-27

Review 5.  The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion.

Authors:  Silvia Carlos; Jokin de Irala; Matt Hanley; Miguel Ángel Martínez-González
Journal:  J Epidemiol Community Health       Date:  2014-06-24       Impact factor: 3.710
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.